Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). (wikipedia.org)
Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia. (drugbank.com)
Remoxipride is a weak selective dopamine D 2 receptor antagonist that was once used in the treatment of schizophrenia. (drugbank.com)
Atypical antipsychotic3
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors. (drugbank.com)
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D 2 receptors. (drugbank.com)
Remoxipride is an atypical antipsychotic dopamine D 2 antagonist. (drugbank.com)
Antagonist3
Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action. (wikipedia.org)
5. The dopamine D(2) antagonist remoxipride (10 mg kg(-1)) did not alter MDMA-induced hyperthermia, but the D(1) antagonist SCH 23390 (0.3 - 2.0 mg kg(-1)) dose-dependently antagonized it. (erowid.org)
On the other hand, (-)-raclopride and remoxipride, two medicines that preferentially bind D2 over D4 receptors had been ineffective, aswell as the selective D3 receptor antagonist U 99194. (cell-metabolism.com)
Dopamine1
1 Remoxipride displays weaker binding to D 2 dopaminergic receptors that dopamine. (drugbank.com)
Receptor antagonist2
Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action. (wikipedia.org)
The current study sought to determine whether the expression of TDF behavioral sensitization could be prevented by the DA D1-like receptor antagonist SCH 23390 (SCH), the DA D2-like receptor antagonist remoxipride (Rem), the competitive NMDA antagonist CPP, or the AMPA antagonist NBQX. (nih.gov)
Schizophrenia2
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). (wikipedia.org)
Risperidone and remoxipride for schizophrenia. (nih.gov)